Please login to the form below

Not currently logged in
Email:
Password:

FDA clears Warner Chilcott osteoporosis drug

Warner Chilcott has won US Food and Drug Administration approval for a new version of its postmenopausal osteoporosis drug Actonel

The Irish pharmaceutical firm Warner Chilcott has won US Food and Drug Administration (FDA) approval for a new version of its Actonel (risedronate sodium) drug, which is a once-weekly treatment for postmenopausal osteoporosis.

The new product will be marketed under the brandname Atelvia and is expected to be launched in early 2011. Unlike Actonel and other drugs in the same class, including Merck's Fosamax (alendronate), Atelvia does not have fasting requirements associated with dosing.

"We believe the dosing convenience of Atelvia sets it apart from other treatment options for osteoporosis patients and provides an opportunity to regain market share in the US in this segment," Roger Boissonneault, president and CEO of Warner Chilcott, said in a statement.

In addition, Atelvia gives Warner Chilcott a new lease on its patent protection for the osteoporosis drug. The patent on the old formulation, which has been a major profit driver for the company, expires in 2014, but Atelvia is patent-protected in the US until 2026.

14th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics